Home/Filings/4/0001181431-12-051162
4//SEC Filing

BARRON BRUCE N 4

Accession 0001181431-12-051162

CIK 0000849636other

Filed

Sep 18, 8:00 PM ET

Accepted

Sep 19, 9:35 AM ET

Size

9.5 KB

Accession

0001181431-12-051162

Insider Transaction Report

Form 4
Period: 2012-08-10
Transactions
  • Other

    Common Stock

    2012-08-10+24,200,50724,200,507 total(indirect: See Footnote)
Transactions
  • Other

    Common Stock

    2012-08-10+24,200,50724,200,507 total(indirect: See Footnote)
Transactions
  • Other

    Common Stock

    2012-08-10+24,200,50724,200,507 total(indirect: See Footnote)
Transactions
  • Other

    Common Stock

    2012-08-10+24,200,50724,200,507 total(indirect: See Footnote)
Footnotes (2)
  • [F1]Received in exchange for 645,556 shares of Pier Pharmaceuticals, Inc. Series A Preferred Stock, a Convertible Promissory Note in the aggregate principal amount of $400,000 and accrued interest thereon, and a stock option to purchase 20,000 shares of Common Stock of Pier Pharmaceuticals, Inc., all in connection with the merger among Cortex Pharmaceuticals, Inc., Pier Pharmaceuticals, Inc. and Pier Acquisition Corp. (the "Merger"). On the effective date of the Merger, the closing price of the Common Stock of Cortex Pharmaceuticals, Inc. was $0.06 per share.
  • [F2]Shares are held of record by Origin Ventures II, L.P. ("OVII"). Origin Ventures II Management, LLC ("OVIIM") is the general partner of OVII. Bruce N. Barron and Steven N. Miller are managing directors of OVIIM and exercise shared voting and investment power with respect to the shares owned by OVII. Each of the reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein.

Issuer

CORTEX PHARMACEUTICALS INC/DE/

CIK 0000849636

Entity typeother

Related Parties

1
  • filerCIK 0000905433

Filing Metadata

Form type
4
Filed
Sep 18, 8:00 PM ET
Accepted
Sep 19, 9:35 AM ET
Size
9.5 KB